Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Gebhart, G.Keyaerts, M.Guiot, T.Flamen, P.Ruiz Borrego, M.Stradella, A.Bermejo De Las Heras, B.Escriva de Romani, S.Calvo-Martinez, L.Ribelles Entrena, N.Martinez, N.Albacar Miro, C. R.Colleoni, M. A.Atienza de Frutos, M.Sampayo-Cordero, M.Cortes, J.Perez Garcia, J. M.Llombart Cussac, A.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21902enOptimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trialconference outputopen access10.1016/j.annonc.2022.03.1091569-8041http://www.annalsofoncology.org/article/S0923753422004884/pdf792494100095